Valuation: Assembly Biosciences, Inc.

Market Cap 68Cr 58Cr 55Cr 50Cr 94Cr 6.53TCr 96Cr 646.98Cr 252.21Cr 3.27TCr 256.34Cr 250.76Cr 11TCr P/E 2026 *
-58.5x
P/E 2027 * -11.5x
Enterprise Value 68Cr 58Cr 55Cr 50Cr 94Cr 6.53TCr 96Cr 646.98Cr 252.21Cr 3.27TCr 256.34Cr 250.76Cr 11TCr EV / Sales 2026 *
11x
EV / Sales 2027 * 21.2x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
1 day+2.76%
1 week+11.95%
Current month+33.53%
1 month+33.80%
3 months+27.68%
6 months+16.63%
Current year-1.41%
1 week 29.83
Extreme 29.83
34.57
1 month 24.5
Extreme 24.5
34.57
Current year 21.8
Extreme 21.795
34.68
1 year 20.23
Extreme 20.23
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
47.28
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Free

Director

8,000 0.0514%
29/03/26 Free

Chief Technology Officer

26,000 0.1671%
08/08/25 BuyCompany 45,91,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
+2.76%+11.95%+28.22%+200.45% 68Cr
+0.32%+4.27%+3.46%+24.84% 5.12TCr
-0.64%+4.82%+485.55%+614.84% 4.54TCr
+2.00%+3.69%+19.34%+91.23% 4.2TCr
-0.00%+6.02%+33.33%+19.66% 4.21TCr
0.00%-3.91%+18.49%+47.98% 3.19TCr
+0.37%+3.48% - - 1.67TCr
-0.05%+5.27%+31.55%+145.37% 1.71TCr
-0.82%+2.58%+6.26%+34.41% 1.48TCr
-0.33%+3.62%+82.64%+46.53% 1.39TCr
Average +0.42%+4.11%+78.76%+136.14% 2.76TCr
Weighted average by Cap. +0.29%+3.20%+103.50%+151.06%

Financials

2026 *2027 *
Net sales 6.2Cr 5.31Cr 4.95Cr 4.55Cr 8.54Cr 593.43Cr 8.71Cr 59Cr 23Cr 297.41Cr 23Cr 23Cr 984.61Cr 3.22Cr 2.76Cr 2.58Cr 2.36Cr 4.44Cr 308.58Cr 4.53Cr 31Cr 12Cr 154.65Cr 12Cr 12Cr 511.99Cr
Net income -1.06Cr -90.86L -84.77L -77.79L -1.46Cr -101.54Cr -1.49Cr -10Cr -3.92Cr -51Cr -3.98Cr -3.9Cr -168.47Cr -6.03Cr -5.16Cr -4.81Cr -4.42Cr -8.3Cr -576.63Cr -8.46Cr -57Cr -22Cr -288.99Cr -23Cr -22Cr -956.73Cr
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
21/26/21 $33.53 -0.92% 2,15,023
19/26/19 $33.84 +5.32% 3,84,565
18/26/18 $32.13 +7.06% 4,84,813
17/26/17 $30.01 -8.92% 3,04,523
14/26/14 $32.95 +10.02% 5,59,108
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
33.53USD
Average target price
50.00USD
Spread / Average Target
+49.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock